Helsinn Investment Fund

About The Fund

Helsinn Investment Fund, also known as 3B Future Health Fund, is a corporate venture arm of the Helsinn Group that focuses on investments in the healthcare sector, particularly in life sciences. They channel funds into privately-owned companies that showcase early-stage technologies and innovations in oncology, biotechnology, pharmaceuticals, medical devices, and food supplements. Based in Luxembourg, the fund's overarching goal is to support US and European-based private early-stage innovative companies that address areas of high unmet patient needs. They are guided by core values—including quality, integrity, and respect—and a strong dedication to science and oncology, aiming to facilitate the introduction of life-changing treatments to patients. Their investment strategy is grounded in backing potential first-in-class assets, revolutionary insights, experienced management teams, and solid investor syndicates. Helsinn Investment Fund places an emphasis on start-up companies and typically engages during Series A funding rounds, sometimes even earlier. They operate with a 10-year fund horizon, with the expectation that investments in target companies will be held for five to eight years, although earlier exits may occur if certain value inflection points are reached. Their portfolio is intended to be a diversified mix of 10-15 companies, with up to $12 million invested in each, and they seek to take Board positions. The geographical focus is 100% healthcare, with a priority on startups based in the US and Europe, focusing mainly on oncology and rare diseases. This strategy leverages the expertise of a team with a track record built on robust due diligence and efficient work processes, and they are willing to reserve capital for follow-on rounds. The fund is also drug modality agnostic, and investments may span across various levels of complexity in science and technology across different geographies.